Previous 10 | Next 10 |
REDWOOD CITY, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the second quarter of 2023 ended June 30, 2023. Re...
REDWOOD CITY, Calif., July 26, 2023 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, today announced the company will present at the upcoming Canaccord Genuity 43 rd Annual Growth Confer...
REDWOOD CITY, Calif., July 17, 2023 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the second quarter of 2023 after the close of trading...
2023-06-23 08:52:10 ET Summary Pulmonx Corporation's entry into the Japan market and momentum in its Zephyr segment are potential catalysts to its market value. The company expects ~100,000 extra patient candidates from the move, adding a meaningful tailwind to long-term sales. ...
2023-05-02 23:55:07 ET Pulmonx Corporation (LUNG) Q1 2023 Earnings Conference Call May 2, 2023 16:30 ET Company Participants Laine Morgan - Investor Relations Glen French - President and Chief Executive Officer Derrick Sung - Chief Financial Officer Confere...
2023-05-02 16:49:36 ET Pulmonx press release ( NASDAQ: LUNG ): Q1 GAAP EPS of -$0.42 beats by $0.02 . Revenue of $14.5M (+34.3% Y/Y) beats by $1.01M . For further details see: Pulmonx GAAP EPS of -$0.42 beats by $0.02, revenue of $14.5M beats by $1.01M
REDWOOD CITY, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the first quarter of 2023 ended March 31, 2023. Rec...
REDWOOD CITY, Calif., April 25, 2023 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be presenting at the Bank of America Securities 2023 Health Care Confere...
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the first quarter of 2023 after the close of trading on Tuesday, May 2, 2023. Company management will host a ...
2023-04-05 23:47:05 ET Summary Pulmonx has an FDA-approved technology to treat severe emphysema, which is estimated to be a $12 billion market. However, adoption rate has been slow and the company has been burning cash. After more than doubling in the past few months, I recomm...
News, Short Squeeze, Breakout and More Instantly...
2024-06-23 01:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
A look at the top 10 most actives in the United States Allarity Therapeutics Inc. (ALLR) rose 97.8% to $2.71 on volume of 44,141,232 shares Faraday Future Intelligent Electric Inc. (FFIE) fell 1.1% to $0.0456 on volume of 28,670,184 shares Emergent Biosolutions Inc. (EBS) rose 67.7% to $3...
REDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in minimally invasive treatments for lung disease, today reported financial results for the quarter ended March 31, 2024. Rec...